A personalized approach to treatment: Use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada

Current Oncology

Volumn 19, Issue 2, 2012, Pages 78-90

  Hirsh, Vera ^a   Melosky, B ^b   Goss, G ^c   Morris, D ^d   Morzycki, W ^e  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d TOM BAKER CANCER CENTRE   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Canadian situation; EGFR; EGFR TKIS; NSCLC

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARBOTAXEL; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NERATINIB; PACLITAXEL; PEMETREXED; PLACEBO; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FATIGUE; FUNCTIONAL STATUS; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC SCREENING; HEMATOLOGIC DISEASE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; QUALITY OF LIFE; RASH; RECEPTOR GENE; RISK BENEFIT ANALYSIS;

EID: 84859474917     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1018     Document Type: Article

References (55)

1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2010. Toronto, ON: Canadian Cancer Society; 2010.
2. United States, National Institutes of Health, National Cancer Institute (nci). General Information About Non-Small Cell Lung Cancer [Web page]. Bethesda, MD: nci; n.d. [Available online at: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional; cited September 12, 2010].
3. Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages i-iii a resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-18.
4. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011;135:110-16.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
6. Cagle PT, Dacic S. Lung cancer and the future of pathology. Arch Pathol Lab Med 2011;135:293-5.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
9. Pao W, Miller V, Zakowski M, et al. egf receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
10. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008;10:242-8.
11. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from egfr-tki treatment for patients with lung cancer? Br J Cancer 2007;96:857-63.
12. Tsao MS, Ionescu G, Chong D, et al. Population-based pan- Canadian EGFR-mutation testing program [abstract e18017]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82932; cited February 8, 2012]
13. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-egfr therapy in common cancers. J Oncol 2009;2009:567486.
14. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 Trial). J Clin Oncol 2003;21:2237-46. [Erratum in: J Clin Oncol 2004;22:4811]
15. Hirsh V. Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 2010;17:13-23.
16. Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to egfr tkis and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011;2011:165214.
17. Jänne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-30.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
19. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase ii study of sequential erlotinib and chemotherapy as firstline treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7.
20. Mok T, Wu YL, Zhang L. A small step towards personalized medicine for non-small cell lung cancer. Discov Med 2009;8:227-31.
21. Ellis PM, Morzycki W, Melosky B, et al. The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol 2009;16:27-48.
22. Sartori G, Cavazza A, Sgambato A, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to egfr inhibitors. Am J Clin Pathol 2009;131:478-89.
23. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas. Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009;63:235-40.
24. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-70.
25. Ontario, Ministry of Health and Long-Term Care, Medical Advisory Secretariat (mas). Epidermal Growth Factor Receptor (EGFR) Genetic Testing for Prediction of Response to EGFR-Targeted (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ontario health technology assessment series. Vol. 10. Iss. 24. Toronto, ON: mas; 2010. [Available online at: http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/EGFR_20101209.pdf; cited September 2011]
26. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering firstline egfr tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7.
27. BC Cancer Agency (bcca). BCCA Protocol Summary for First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib. Vancouver, BC: bcca; 2010.
28. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-5.
29. Voon PJ, Chul Cho B, Yeo WL, Soo RA. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J Thorac Dis 2010;2:144-53.
30. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall- cell lung cancer: a phase iii trial-intact 1. J Clin Oncol 2004;22:777-84.
31. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall- cell lung cancer: a phase iii trial-intact 2. J Clin Oncol 2004;22:785-94.
32. Herbst RS, Prager D, Hermann R, et al. tribute: a phase iii trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
33. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52.
34. Lee JS, Park K, SW K, et al. A randomized phase iii study of gefitinib (Iressa) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract PRS.4]. J Thorac Oncol 2009;4(suppl 1):S283.
35. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
36. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
37. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
38. Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomized phase iii optimal (ctonG 0802) study comparing first-line erlotinib versus carboplatin (cbdca) plus gemcitabine (gem), in Chinese advanced nonsmall-cell lung cancer (nsclc) patients (pts) with EGFR activating mutations [abstract LBA13]. Ann Oncol 2010;21(suppl 8):viii6.
39. Rosell R, Gervais R, Vergnenegre A et al. Erlotinib versus chemotherapy (ct) in advanced non-small cell lung cancer (nsclc) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (eurtac) phase iii randomized trial [abstract 7503]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78285; cited February 8, 2012]
40. AstraZeneca Canada. IRESSA (Gefitinib Tablets) [product monograph]. Mississauga, ON: AstraZeneca Canada; 2009.
41. Mok TSK, Spigel DR, Park K, et al. Efficacy and safety of PF299804 as first-line treatment (tx) of patients (pts) with advanced (adv) nsclc selected for activating mutation (mu) of epidermal growth factor receptor (egfr). Ann Oncol 2010;21(suppl 8):viii1-12.
42. Yang C, Shih J, Su W, et al. A phase ii study of BIBW 2992 in patients with adenocarcinoma of the lung and activating egfr/ her1 mutations (LUX-Lung 2) [abstract 7521]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50532; cited February 8, 2012]
43. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000;18:2095-103.
44. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
45. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372:1809-18.
46. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase iii study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52.
47. Lee DH, Park K, Kim JH, et al. Randomized phase iii trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14.
48. Vamvakas L, Agelaki S, Kentepozidis NK, et al. Pemetrexed (mta) compared with erlotinib (erl) in pretreated patients with advanced non-small cell lung cancer (nsclc): results of a randomized phase iii Hellenic Oncology Research Group trial [abstract 7519]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=43881; cited February 8, 2012]
49. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
50. Hirsh V, Cadranel J, Cong J, et al. Symptom and health-related quality of life benefit of afatinib (BIBW 2992) in advanced nsclc patients previously treated with erlotinib or gefitinib: results of a randomized phase iii trial (LUX-Lung 1) [abstract 011.07]. J Thorac Oncol 2011;6(suppl 2):S324.
51. Miller VA, Hirsh V, Cadranal J, et al. Subgroup analysis of LUX-Lung 1: a randomized phase iii trial of afatinib (BIBW 2992) + best supportive care (bsc) versus placebo + bsc in patients failing 1-2 lines of chemotherapy and erlotinib or gefitinib [abstract LBPL3]. J Thorac Oncol 2010;5 (suppl 7):S557.
52. Ramalingam SS, Boyer MJ, Park K, et al. Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (egfr) inhibitor, versus (v) erlotinib (e) in patients (pts) with advanced non-small cell lung cancer (nsclc) after chemotherapy (ct) failure: quantitative and qualitative benefits [abstract 365PD]. Ann Oncol 2010;21(suppl 8):viii122.
53. Janne PA, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced nsclc after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (e): a two-arm, phase ii trial [abstract 8063]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32872; cited February 8, 2012]
54. Hoffmann-La Roche. Product Monograph: Tarceva (Erlotinib Hydrochloride Tablets). Mississauga, ON: Hoffmann-La Roche; 2005.
55. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011;18:126-38.